Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.

Particles engineered to engage and interact with cell surface ligands and to modulate cells can be harnessed to explore basic biological questions as well as to devise cellular therapies. Biology has inspired the design of these particles, such as artificial antigen-presenting cells (aAPCs) for use in immunotherapy. While much has been learned about mimicking antigen presenting cell biology, as we decrease the size of aAPCs to the nanometer scale, we need to extend biomimetic design to include considerations of T cell biology-including T-cell receptor (TCR) organization. Here we describe the first quantitative analysis of particle size effect on aAPCs with both Signals 1 and 2 based on T cell biology. We show that aAPCs, larger than 300 nm, activate T cells more efficiently than smaller aAPCs, 50 nm. The 50 nm aAPCs require saturating doses or require artificial magnetic clustering to activate T cells. Increasing ligand density alone on the 50 nm aAPCs did not increase their ability to stimulate CD8+ T cells, confirming the size-dependent phenomenon. These data support the need for multireceptor ligation and activation of T-cell receptor (TCR) nanoclusters of similar sizes to 300 nm aAPCs. Quantitative analysis and modeling of a nanoparticle system provides insight into engineering constraints of aAPCs for T cell immunotherapy applications and offers a case study for other cell-modulating particles.

[1]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[2]  J. Schneck,et al.  Linking form to function: Biophysical aspects of artificial antigen presenting cell design. , 2015, Biochimica et biophysica acta.

[3]  A. Lanzavecchia,et al.  From TCR Engagement to T Cell Activation A Kinetic View of T Cell Behavior , 1999, Cell.

[4]  M. Jenkins,et al.  The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude , 2012, The Journal of Immunology.

[5]  Yuval Dor,et al.  Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. , 2005, Genes & development.

[6]  Ronnie H. Fang,et al.  Nanoparticle-Based Modulation of the Immune System. , 2016, Annual review of chemical and biomolecular engineering.

[7]  A. Mackensen,et al.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.

[8]  G. Nolan,et al.  Duration of antigen receptor signaling determines T-cell tolerance or activation , 2010, Proceedings of the National Academy of Sciences.

[9]  Cheng Zhu,et al.  Insights from in situ analysis of TCR–pMHC recognition: response of an interaction network , 2013, Immunological reviews.

[10]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[11]  J. Yewdell,et al.  Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters , 2012, Proceedings of the National Academy of Sciences.

[12]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[13]  H. Eisen,et al.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.

[14]  S. Ugel,et al.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. , 2009, Cancer research.

[15]  Levi A. Gheber,et al.  Domains in cell plasma membranes investigated by near-field scanning optical microscopy. , 1998, Biophysical journal.

[16]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[17]  Tarek R. Fadel,et al.  Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. , 2008, Nano letters.

[18]  A. Scheffold,et al.  Fine Tuning and Efficient T Cell Activation with Stimulatory aCD3 Nanoarrays , 2013, Nano letters.

[19]  Robert L. Tanguay,et al.  Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. , 2017, Nature nanotechnology.

[20]  Thomas M. Schmitt,et al.  Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients , 2013, Science Translational Medicine.

[21]  Jonathan P Schneck,et al.  Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. , 2014, Biomaterials.

[22]  Cheng Zhu,et al.  The kinetics of two dimensional TCR and pMHC interactions determine T cell responsiveness , 2010, Nature.

[23]  J. Sunshine,et al.  Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. , 2015, Small.

[24]  M. Edidin,et al.  Magnetic Field-Induced T Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity , 2014, ACS nano.

[25]  Ronald D. Vale,et al.  A DNA-Based T Cell Receptor Reveals a Role for Receptor Clustering in Ligand Discrimination , 2016, Cell.

[26]  Weiguo Lu,et al.  Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma , 2010, Journal of experimental & clinical cancer research : CR.

[27]  Mark M Davis,et al.  TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation , 2010, Nature Immunology.

[28]  B. Alarcón,et al.  Cognate Peptide–MHC Complexes Are Expressed as Tightly Apposed Nanoclusters in Virus-Infected Cells To Allow TCR Crosslinking , 2014, The Journal of Immunology.

[29]  Mark M. Davis,et al.  Determination of the Relationship Between T Cell Responsiveness and the Number of MHC-Peptide Complexes Using Specific Monoclonal Antibodies1 , 2000, The Journal of Immunology.

[30]  J. Green,et al.  Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. , 2017, Biomaterials.

[31]  M. Luscher,et al.  Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis , 1991, Nature.

[32]  Warren C W Chan,et al.  Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.

[33]  Daniel Coombs,et al.  Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time , 2010, Immunity.

[34]  R C Brower,et al.  Minimal requirements for peptide mediated activation of CD8+ CTL. , 1994, Molecular immunology.

[35]  Penelope A. Morel,et al.  Dominant Role of Antigen Dose in CD4+Foxp3+ Regulatory T Cell Induction and Expansion1 , 2009, The Journal of Immunology.

[36]  H. Grey,et al.  The minimal number of class II MHC-antigen complexes needed for T cell activation. , 1990, Science.

[37]  Tarek R. Fadel,et al.  A carbon nanotube-polymer composite for T-cell therapy. , 2014, Nature nanotechnology.

[38]  Michael Loran Dustin,et al.  T Cell Activation is Determined by the Number of Presented Antigens , 2013, Nano letters.

[39]  S. K. Watkins,et al.  Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells , 2012, Cancer Immunology, Immunotherapy.

[40]  Tarek R. Fadel,et al.  An Artificial Antigen-presenting Cell with Paracrine Delivery of IL-2 Impacts the Magnitude and Direction of the T Cell Response* , 2011, The Journal of Biological Chemistry.

[41]  K. Kinzler,et al.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. , 2015, ACS nano.

[42]  A. Riva,et al.  Altered maturation of peripheral blood dendritic cells in patients with breast cancer , 2003, British Journal of Cancer.

[43]  P. Roche,et al.  Major Histocompatibility Complex (MHC) Class II-Peptide Complexes Arrive at the Plasma Membrane in Cholesterol-rich Microclusters* , 2013, The Journal of Biological Chemistry.

[44]  O. Eremin,et al.  Dendritic cells are dysfunctional in patients with operable breast cancer , 2004, Cancer Immunology, Immunotherapy.

[45]  Evan W. Newell,et al.  TCR–peptide–MHC interactions in situ show accelerated kinetics and increased affinity , 2010, Nature.

[46]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[47]  Gigi Kwik Grönvall,et al.  Clustering Class I MHC Modulates Sensitivity of T Cell Recognition1 , 2006, The Journal of Immunology.

[48]  Emil R. Unanue,et al.  Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation , 1990, Nature.

[49]  Michael Loran Dustin,et al.  T Cell Receptor Signaling Precedes Immunological Synapse Formation , 2002, Science.

[50]  P. Lenne,et al.  Molecular clustering in the cell: from weak interactions to optimized functional architectures. , 2016, Current opinion in cell biology.

[51]  J. L. Santos,et al.  Control of polymeric nanoparticle size to improve therapeutic delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[52]  H. Grey,et al.  The minimal number of antigen‐major histocompatibility complex class II complexes required for activation of naive and primed T cells , 1997, European journal of immunology.

[53]  Mark M Davis,et al.  T cell killing does not require the formation of a stable mature immunological synapse , 2004, Nature Immunology.

[54]  A. Mackensen,et al.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Greg M. Delgoffe,et al.  Anergic T Cells Are Metabolically Anergic1 , 2009, The Journal of Immunology.

[56]  D. Bray,et al.  Receptor clustering as a cellular mechanism to control sensitivity , 1998, Nature.

[57]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[58]  P. Schwille,et al.  Cholesterol and Sphingomyelin Drive Ligand-independent T-cell Antigen Receptor Nanoclustering* , 2012, The Journal of Biological Chemistry.

[59]  Michael Loran Dustin,et al.  Nanoscale ligand spacing influences receptor triggering in T cells and NK cells. , 2013, Nano letters.

[60]  M. Jackson,et al.  High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Pau Serra,et al.  Reversal of autoimmunity by boosting memory-like autoregulatory T cells. , 2010, Immunity.

[62]  M. Edidin,et al.  Nanoscale artificial antigen presenting cells for T cell immunotherapy. , 2014, Nanomedicine : nanotechnology, biology, and medicine.